Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.

@article{Mita2011PhaseIS,
  title={Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.},
  author={Monica M. Mita and K. R. Kelly and Alain C. Mita and Alejandro D. Ricart and Ofelia Romero and Anthony A Tolcher and Laurel Hook and Chukwuemeka S Okereke and Ilya Krivelevich and Daniel P. Rossignol and Francis J Giles and Eric K. Rowinsky and Chris H M Takimoto},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2011},
  volume={17 1},
  pages={193-200}
}
PURPOSE This phase I study was conducted to characterize the safety profile, pharmacokinetics, pharmacodynamics, dose-limiting toxicity (DLT), and the maximum-tolerated dose of E7820, a novel oral sulfonamide derivative with antiangiogenic properties, when administered to patients with advanced solid malignancies. PATIENTS AND METHODS Patients received single daily doses of E7820 orally for 28 days in cycle 1, followed by a 7-day no-treatment period, after which time-uninterrupted daily… CONTINUE READING
Highly Cited
This paper has 47 citations. REVIEW CITATIONS

References

Publications referenced by this paper.
Showing 1-10 of 23 references

A phase I study of E7820 in combination with Cetuximab in patients (pts) with advanced solid tumors

  • S El-Khoueiry ABI, K Feit, HJ Lenz
  • J Clin Oncol 2008;26(Suppl):abstr3568
  • 2008
Highly Influential
3 Excerpts

Predictingbenefit fromantiangiogenic agents in malignancy

  • OatesAJ JubbAM, KoeppenH HoldenS
  • Nat Rev Cancer
  • 2006

Down - regulation of integrin alpha 2 surface expression by mutant epidermal growth factor receptor ( EGFRvIII ) induces aberrant cell spreading and focal adhesion formation

  • ZeineldinR NingY, RosenbergM LiuY, HudsonLG StackMS
  • Cancer Res
  • 2005

Similar Papers

Loading similar papers…